Copenhagen, 2014-12-30 13:13 CET (GLOBE NEWSWIRE) -- Copenhagen, 30 December 2014 – Zealand Pharma (Nasdaq Copenhagen: ZEAL) announces the following dates for the company’s planned financial reporting in 2015:
13 March Full year announcement and Annual Report 2014
22 May Interim report for 1st quarter 2015
28 August Interim report for 1st half 2015
5 November Interim report for the first 9 months of 2015
Zealand’s Annual General Meeting for 2015 will be held on 21 April 2015.
***
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and in-house competences also in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide (a once-daily prandial GLP-1 agonist) is marketed globally (ex-US) by Sanofi as Lyxumia® for the treatment of Type 2 diabetes. Sanofi also has the product in Phase III development as a single-injection combination with Lantus® (LixiLan) under a global license agreement. US regulatory filing of Lyxumia® is planned for summer 2015 and of LixiLan as early as end 2015.
Zealand proprietary pipeline includes danegaptide (prevention of ischemic reperfusion injury) and ZP4207 (a stable glucagon product to treat severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com
Follow us on Twitter @ZealandPharma
